Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone

Katalin Nagy, Bernadett Marko, Gabriella Zsilla, Peter Matyus, Katalin Pallagi, Geza Szabo, Zsolt Juranyi, Jozsef Barkoczy, Gyorgy Levay, Laszlo G. Harsing

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The most dominant hypotheses for the pathogenesis of schizophrenia have focused primarily upon hyperfunctional dopaminergic and hypofunctional glutamatergic neurotransmission in the central nervous system. The therapeutic efficacy of all atypical antipsychotics is explained in part by antagonism of the dopaminergic neurotransmission, mainly by blockade of D2 dopamine receptors. N-methyl-d-aspartate (NMDA) receptor hypofunction in schizophrenia can be reversed by glycine transporter type-1 (GlyT-1) inhibitors, which regulate glycine concentrations at the vicinity of NMDA receptors. Combined drug administration with D2 dopamine receptor blockade and activation of hypofunctional NMDA receptors may be needed for a more effective treatment of positive and negative symptoms and the accompanied cognitive deficit in schizophrenia. To investigate this type of combined drug administration, rats were treated with the atypical antipsychotic risperidone together with the GlyT-1 inhibitor Org-24461. Brain microdialysis was applied in the striatum of conscious rats and determinations of extracellular dopamine, DOPAC, HVA, glycine, glutamate, and serine concentrations were carried out using HPLC/electrochemistry. Risperidone increased extracellular concentrations of dopamine but failed to influence those of glycine or glutamate measured in microdialysis samples. Org-24461 injection reduced extracellular dopamine concentrations and elevated extracellular glycine levels but the concentrations of serine and glutamate were not changed. When risperidone and Org-24461 were added in combination, a decrease in extracellular dopamine concentrations was accompanied with sustained elevation of extracellular glycine levels. Interestingly, the extracellular concentrations of glutamate were also enhanced. Our data indicate that coadministration of an antipsychotic with a GlyT-1 inhibitor may normalize hypofunctional NMDA receptor-mediated glutamatergic neurotransmission with reduced dopaminergic side effects characteristic for antipsychotic medication.

Original languageEnglish
Pages (from-to)2096-2106
Number of pages11
JournalNeurochemical Research
Volume35
Issue number12
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Glycine Plasma Membrane Transport Proteins
Risperidone
Glycine
Dopamine
Brain
Antipsychotic Agents
Glutamic Acid
Synaptic Transmission
Schizophrenia
Dopamine D2 Receptors
Microdialysis
Serine
Rats
Electrochemistry
3,4-Dihydroxyphenylacetic Acid
Dopamine Agents
Neurobehavioral Manifestations
Neurology
Pharmaceutical Preparations
Central Nervous System

Keywords

  • Antipsychotic agents
  • Extracellular glycine and dopamine
  • Glycine transporter type-1 inhibitors
  • Microdialysis
  • Schizophrenia

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Biochemistry

Cite this

Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone. / Nagy, Katalin; Marko, Bernadett; Zsilla, Gabriella; Matyus, Peter; Pallagi, Katalin; Szabo, Geza; Juranyi, Zsolt; Barkoczy, Jozsef; Levay, Gyorgy; Harsing, Laszlo G.

In: Neurochemical Research, Vol. 35, No. 12, 12.2010, p. 2096-2106.

Research output: Contribution to journalArticle

Nagy, Katalin ; Marko, Bernadett ; Zsilla, Gabriella ; Matyus, Peter ; Pallagi, Katalin ; Szabo, Geza ; Juranyi, Zsolt ; Barkoczy, Jozsef ; Levay, Gyorgy ; Harsing, Laszlo G. / Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone. In: Neurochemical Research. 2010 ; Vol. 35, No. 12. pp. 2096-2106.
@article{dfc65358d3e14c4a8889c87f4e5295c4,
title = "Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone",
abstract = "The most dominant hypotheses for the pathogenesis of schizophrenia have focused primarily upon hyperfunctional dopaminergic and hypofunctional glutamatergic neurotransmission in the central nervous system. The therapeutic efficacy of all atypical antipsychotics is explained in part by antagonism of the dopaminergic neurotransmission, mainly by blockade of D2 dopamine receptors. N-methyl-d-aspartate (NMDA) receptor hypofunction in schizophrenia can be reversed by glycine transporter type-1 (GlyT-1) inhibitors, which regulate glycine concentrations at the vicinity of NMDA receptors. Combined drug administration with D2 dopamine receptor blockade and activation of hypofunctional NMDA receptors may be needed for a more effective treatment of positive and negative symptoms and the accompanied cognitive deficit in schizophrenia. To investigate this type of combined drug administration, rats were treated with the atypical antipsychotic risperidone together with the GlyT-1 inhibitor Org-24461. Brain microdialysis was applied in the striatum of conscious rats and determinations of extracellular dopamine, DOPAC, HVA, glycine, glutamate, and serine concentrations were carried out using HPLC/electrochemistry. Risperidone increased extracellular concentrations of dopamine but failed to influence those of glycine or glutamate measured in microdialysis samples. Org-24461 injection reduced extracellular dopamine concentrations and elevated extracellular glycine levels but the concentrations of serine and glutamate were not changed. When risperidone and Org-24461 were added in combination, a decrease in extracellular dopamine concentrations was accompanied with sustained elevation of extracellular glycine levels. Interestingly, the extracellular concentrations of glutamate were also enhanced. Our data indicate that coadministration of an antipsychotic with a GlyT-1 inhibitor may normalize hypofunctional NMDA receptor-mediated glutamatergic neurotransmission with reduced dopaminergic side effects characteristic for antipsychotic medication.",
keywords = "Antipsychotic agents, Extracellular glycine and dopamine, Glycine transporter type-1 inhibitors, Microdialysis, Schizophrenia",
author = "Katalin Nagy and Bernadett Marko and Gabriella Zsilla and Peter Matyus and Katalin Pallagi and Geza Szabo and Zsolt Juranyi and Jozsef Barkoczy and Gyorgy Levay and Harsing, {Laszlo G.}",
year = "2010",
month = "12",
doi = "10.1007/s11064-010-0241-0",
language = "English",
volume = "35",
pages = "2096--2106",
journal = "Neurochemical Research",
issn = "0364-3190",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone

AU - Nagy, Katalin

AU - Marko, Bernadett

AU - Zsilla, Gabriella

AU - Matyus, Peter

AU - Pallagi, Katalin

AU - Szabo, Geza

AU - Juranyi, Zsolt

AU - Barkoczy, Jozsef

AU - Levay, Gyorgy

AU - Harsing, Laszlo G.

PY - 2010/12

Y1 - 2010/12

N2 - The most dominant hypotheses for the pathogenesis of schizophrenia have focused primarily upon hyperfunctional dopaminergic and hypofunctional glutamatergic neurotransmission in the central nervous system. The therapeutic efficacy of all atypical antipsychotics is explained in part by antagonism of the dopaminergic neurotransmission, mainly by blockade of D2 dopamine receptors. N-methyl-d-aspartate (NMDA) receptor hypofunction in schizophrenia can be reversed by glycine transporter type-1 (GlyT-1) inhibitors, which regulate glycine concentrations at the vicinity of NMDA receptors. Combined drug administration with D2 dopamine receptor blockade and activation of hypofunctional NMDA receptors may be needed for a more effective treatment of positive and negative symptoms and the accompanied cognitive deficit in schizophrenia. To investigate this type of combined drug administration, rats were treated with the atypical antipsychotic risperidone together with the GlyT-1 inhibitor Org-24461. Brain microdialysis was applied in the striatum of conscious rats and determinations of extracellular dopamine, DOPAC, HVA, glycine, glutamate, and serine concentrations were carried out using HPLC/electrochemistry. Risperidone increased extracellular concentrations of dopamine but failed to influence those of glycine or glutamate measured in microdialysis samples. Org-24461 injection reduced extracellular dopamine concentrations and elevated extracellular glycine levels but the concentrations of serine and glutamate were not changed. When risperidone and Org-24461 were added in combination, a decrease in extracellular dopamine concentrations was accompanied with sustained elevation of extracellular glycine levels. Interestingly, the extracellular concentrations of glutamate were also enhanced. Our data indicate that coadministration of an antipsychotic with a GlyT-1 inhibitor may normalize hypofunctional NMDA receptor-mediated glutamatergic neurotransmission with reduced dopaminergic side effects characteristic for antipsychotic medication.

AB - The most dominant hypotheses for the pathogenesis of schizophrenia have focused primarily upon hyperfunctional dopaminergic and hypofunctional glutamatergic neurotransmission in the central nervous system. The therapeutic efficacy of all atypical antipsychotics is explained in part by antagonism of the dopaminergic neurotransmission, mainly by blockade of D2 dopamine receptors. N-methyl-d-aspartate (NMDA) receptor hypofunction in schizophrenia can be reversed by glycine transporter type-1 (GlyT-1) inhibitors, which regulate glycine concentrations at the vicinity of NMDA receptors. Combined drug administration with D2 dopamine receptor blockade and activation of hypofunctional NMDA receptors may be needed for a more effective treatment of positive and negative symptoms and the accompanied cognitive deficit in schizophrenia. To investigate this type of combined drug administration, rats were treated with the atypical antipsychotic risperidone together with the GlyT-1 inhibitor Org-24461. Brain microdialysis was applied in the striatum of conscious rats and determinations of extracellular dopamine, DOPAC, HVA, glycine, glutamate, and serine concentrations were carried out using HPLC/electrochemistry. Risperidone increased extracellular concentrations of dopamine but failed to influence those of glycine or glutamate measured in microdialysis samples. Org-24461 injection reduced extracellular dopamine concentrations and elevated extracellular glycine levels but the concentrations of serine and glutamate were not changed. When risperidone and Org-24461 were added in combination, a decrease in extracellular dopamine concentrations was accompanied with sustained elevation of extracellular glycine levels. Interestingly, the extracellular concentrations of glutamate were also enhanced. Our data indicate that coadministration of an antipsychotic with a GlyT-1 inhibitor may normalize hypofunctional NMDA receptor-mediated glutamatergic neurotransmission with reduced dopaminergic side effects characteristic for antipsychotic medication.

KW - Antipsychotic agents

KW - Extracellular glycine and dopamine

KW - Glycine transporter type-1 inhibitors

KW - Microdialysis

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=78651340371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651340371&partnerID=8YFLogxK

U2 - 10.1007/s11064-010-0241-0

DO - 10.1007/s11064-010-0241-0

M3 - Article

C2 - 20725779

AN - SCOPUS:78651340371

VL - 35

SP - 2096

EP - 2106

JO - Neurochemical Research

JF - Neurochemical Research

SN - 0364-3190

IS - 12

ER -